The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report
Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity according to magnetic resonance imaging. The drug was...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ZAO "Consilium Medicum"
2023-05-01
|
| Series: | Consilium Medicum |
| Subjects: | |
| Online Access: | https://consilium.orscience.ru/2075-1753/article/viewFile/553315/132684 |
| _version_ | 1797767080557150208 |
|---|---|
| author | Denis S. Korobko Ivan Ie. Arkhipov Anna I. Prokaeva Ekaterina V. Tret'iakova |
| author_facet | Denis S. Korobko Ivan Ie. Arkhipov Anna I. Prokaeva Ekaterina V. Tret'iakova |
| author_sort | Denis S. Korobko |
| collection | DOAJ |
| description | Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity according to magnetic resonance imaging. The drug was approved in Russia at the end of December 2020. The efficacy of siponimod was confirmed in EXPAND study, a large, randomized, double-blind phase III clinical study. This article presents three clinical cases of patients with secondary progressive multiple sclerosis from the practice of specialists of the Novosibirsk Center for Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System with an analysis of patients selection for siponimod treatment and an assessment of the therapy effectiveness. |
| first_indexed | 2024-03-12T20:34:24Z |
| format | Article |
| id | doaj.art-88dcd9e5d40947958cc5a9d2a973db28 |
| institution | Directory Open Access Journal |
| issn | 2075-1753 2542-2170 |
| language | Russian |
| last_indexed | 2024-03-12T20:34:24Z |
| publishDate | 2023-05-01 |
| publisher | ZAO "Consilium Medicum" |
| record_format | Article |
| series | Consilium Medicum |
| spelling | doaj.art-88dcd9e5d40947958cc5a9d2a973db282023-08-01T15:29:19ZrusZAO "Consilium Medicum"Consilium Medicum2075-17532542-21702023-05-012529510010.26442/20751753.2023.2.2022294692The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case reportDenis S. Korobko0https://orcid.org/0000-0002-7938-3782Ivan Ie. Arkhipov1https://orcid.org/0000-0003-2740-6388Anna I. Prokaeva2https://orcid.org/0000-0003-2541-9302Ekaterina V. Tret'iakova3State Novosibirsk Regional Clinical HospitalState Novosibirsk Regional Clinical HospitalState Novosibirsk Regional Clinical HospitalState Novosibirsk Regional Clinical HospitalSiponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity according to magnetic resonance imaging. The drug was approved in Russia at the end of December 2020. The efficacy of siponimod was confirmed in EXPAND study, a large, randomized, double-blind phase III clinical study. This article presents three clinical cases of patients with secondary progressive multiple sclerosis from the practice of specialists of the Novosibirsk Center for Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System with an analysis of patients selection for siponimod treatment and an assessment of the therapy effectiveness.https://consilium.orscience.ru/2075-1753/article/viewFile/553315/132684siponimodsecondary progressive multiple sclerosisclinical case |
| spellingShingle | Denis S. Korobko Ivan Ie. Arkhipov Anna I. Prokaeva Ekaterina V. Tret'iakova The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report Consilium Medicum siponimod secondary progressive multiple sclerosis clinical case |
| title | The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report |
| title_full | The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report |
| title_fullStr | The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report |
| title_full_unstemmed | The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report |
| title_short | The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report |
| title_sort | first cases of using targeted therapy for secondary progressive multiple sclerosis in russia case report |
| topic | siponimod secondary progressive multiple sclerosis clinical case |
| url | https://consilium.orscience.ru/2075-1753/article/viewFile/553315/132684 |
| work_keys_str_mv | AT denisskorobko thefirstcasesofusingtargetedtherapyforsecondaryprogressivemultiplesclerosisinrussiacasereport AT ivaniearkhipov thefirstcasesofusingtargetedtherapyforsecondaryprogressivemultiplesclerosisinrussiacasereport AT annaiprokaeva thefirstcasesofusingtargetedtherapyforsecondaryprogressivemultiplesclerosisinrussiacasereport AT ekaterinavtretiakova thefirstcasesofusingtargetedtherapyforsecondaryprogressivemultiplesclerosisinrussiacasereport AT denisskorobko firstcasesofusingtargetedtherapyforsecondaryprogressivemultiplesclerosisinrussiacasereport AT ivaniearkhipov firstcasesofusingtargetedtherapyforsecondaryprogressivemultiplesclerosisinrussiacasereport AT annaiprokaeva firstcasesofusingtargetedtherapyforsecondaryprogressivemultiplesclerosisinrussiacasereport AT ekaterinavtretiakova firstcasesofusingtargetedtherapyforsecondaryprogressivemultiplesclerosisinrussiacasereport |